Vasoconstrictive decongestants:
the French authorities' dithering leaves patients in danger
- Patients must be protected from the life-threatening adverse effects of vasoconstrictive decongestants used to treat simple colds. Simple market withdrawal is the best option.
- The French authorities' procrastination illustrates their incapacity to take timely decisions on drug safety and thereby to fulfil their primary mission: to protect patients.
Vasoconstrictive drugs: poisoning in children
- In October 2012 the U.S. Food and Drug Administration published an analysis of 96 cases of accidental ingestion of vasoconstrictive nasal decongestants and eyedrops by children.
- The severity of these paediatric cases is a further reason not to use decongestants.
- Vasoconstrictive nasopharyngeal decongestants should simply be taken off the market.
Full text available for free download.
©Prescrire 1 March 2013
Prescrire Int 2013; 22 (136): 72. (Pdf, free)